Douglas E. Gladstone

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel et al. · Blood · 2015 · 300 citations · Full text

Medicine, Hematology, Immunology +14

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani et al. · Leukemia · 2018 · 247 citations · Full text

Medicine, Oncology, Pharmacology +16

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

Yvette L. Kasamon, Javier Bolaños‐Meade, Gabrielle T. Prince et al. · Journal of Clinical Oncology · 2015 · 239 citations

Medicine, Hematology, Immunology +17

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Christopher G. Kanakry, Hua-Ling Tsai, Javier Bolaños‐Meade et al. · Blood · 2014 · 198 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry et al. · Haematologica · 2016 · 188 citations · Full text

Medicine, Hematology, Immunology +17